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Synopsis 22 
Objectives: This study assessed multidrug resistant (MDR) invasive isolates of Streptococcus 23 
pneumoniae, in relation to the serotype evolution, in Canada between 2011 and 2015 as part of the 24 
annual SAVE study. 25 
Methods:  As part of a collaboration between the Canadian Antimicrobial Resistance Alliance and Public 26 
Health Agency of Canada-National Microbiology Laboratory, 6207 invasive isolates of S. pneumoniae 27 
were evaluated.  All isolates were serotyped and had antimicrobial susceptibility testing performed, in 28 
accordance with CLSI guidelines (M07-A10, 2015).  Complete susceptibility profiles were available for 29 
6001 isolates.  MDR was defined as resistance to three or more classes of antimicrobial agents (with 30 
penicillin MIC ≥2 mg/L defined as resistant). 31 
Results:  The overall rate of MDR S. pneumoniae was 6.2% (372/6001) in SAVE; decreasing significantly 32 
from 8.5% in 2011 to 5.6% in 2015 (P=0.0041).  MDR was observed in 32 serotypes with serotypes 15A 33 
and 19A predominating (26.6% and 41.7% of the MDR isolates, respectively).  The overall proportion of 34 
serotypes 19A, 7F and 33A decreased significantly (P<0.0001) throughout the study.  The annual 35 
proportion of serotypes 7C, 8, 9N, 10A, 20, 24F, 29, 31, 33F, 35B and 38 increased throughout the study; 36 
however, among those increasing serotypes, MDR was only notable (>5%) for 24F and 33F.               37 
Conclusions: In 2015, 56.3% of invasive MDR S. pneumoniae were serotypes included in the PCV-13 38 
vaccine.  PCV-13 includes the most commonly identified serotype 19A, however other increasingly 39 
important MDR serotypes such as 15A, 24F and 33F, are notably not in the currently used vaccines. 40 
41 
Introduction 42 
Streptococcus pneumoniae is recognized as an important pathogen worldwide as it is a common cause 43 
of respiratory infections, including community-acquired pneumonia, and the causative agent of Invasive 44 
Pneumococcal Disease (IPD).  The overall incidence rate of IPD in Canada had been reported as 45 
remaining relatively stable with an average of 9.6 cases per 100 000 population during the time period 46 
of 2009 to 2014.1,2  However, the crude incidence rate of IPD in Canada decreased significantly by 2014 47 
to 8.9 cases per 100 000 population with notable decreases in incidence in children less than 5 years of 48 
age.1,3          49 
Prevnar®, a 7-valent pneumococcal conjugate vaccine (PCV-7) including serotypes 4, 6B, 9V, 14, 50 
18C, 19F and 23F, was incorporated in routine vaccination schedules in all Canadian provinces between 51 
2002 and 2006.4   The use of PCV-7 resulted in significant reductions in invasive infections due to S. 52 
pneumoniae as well as reductions in the incidence of recurrent upper respiratory tract infections in 53 
children in North America.4,5,6  Increases in non-vaccine serotypes, particularly MDR serotype 19A, were 54 
rapidly observed following the introduction of PCV-7.4,5  Subsequently, newer pneumococcal conjugate 55 
vaccines were developed with enhanced serotype coverage, including Synflorix™, with the additional 56 
inclusion of serotypes 1, 5 and 7F (PCV-10), and Prevnar®13, which includes serotypes 1, 3, 5, 6A, 7F and 57 
19A (PCV-13).  The broader serotype coverage and the critical inclusion of serotype 19A in PCV-13 58 
offered an important advancement in the protection of children against invasive S. pneumoniae 59 
infections. The immunization guidelines were updated in 2010 to recommend the routine use of PCV-13 60 
in infant vaccine schedules in North America.7,8  The replacement of PCV-7 with PCV-13 as part of 61 
routine infant vaccinations was completed in Canada by early-2011.2    62 
Subsequent to the successful implementation of conjugate vaccines in the routine infant 63 
immunization programs, the efficacy of PCV-13 in the prevention of IPD and community-acquired 64 
pneumonia in immunocompetent adults was evaluated.  The CAPiTA study demonstrated efficacy in the 65 
prevention of pneumococcal pneumonia and IPD for S. pneumoniae with serotypes included in PCV-13.9  66 
Accordingly, the immunization recommendations were updated in North America to include routine 67 
administration of PCV-13 to healthy adults ≥65 years.3,10   68 
Despite the overall success of the vaccine programs, treatment concerns have remained as 69 
many serotypes that were commonly penicillin-resistant or MDR, such as 15A and 19A, have persisted or 70 
increased with the changing epidemiology in the vaccine era.  Penicillin resistance was commonly 71 
observed in serotypes 19A, 19F and 35B in the United States shortly after the introduction of PCV-13.11  72 
Resistance to one or more antibiotics in emerging non-PCV-13 serotypes was recently observed in 73 
serotypes 12F, 15A, 24F and 35B in France.12  Similarly, a high prevalence of MDR non-vaccine serotypes 74 
were observed in Bulgaria five years after the introduction of PCV-10.13 75 
The S. pneumoniae Serotyping and Antimicrobial Susceptibility: Assessment for Vaccine Efficacy 76 
in Canada (SAVE) study is an annual study which began in 2011. The purpose of this study was to 77 
evaluate changes in antimicrobial resistance, particularly multidrug resistance, in relation to serotype 78 
evolution in Canada between 2011 and 2015, subsequent to the introduction of PCV-13.   79 
 80 
Materials and methods 81 
Bacterial isolates 82 
From January 2011 to December 2015, S. pneumoniae isolated from sterile body sites by participating 83 
Canadian provincial public health and hospital laboratories were forwarded to the Public Health Agency 84 
of Canada-National Microbiology Laboratory (PHAC-NML) in Winnipeg, Canada.  As part of an ongoing 85 
collaboration between the Canadian Antimicrobial Resistance Alliance (CARA) and PHAC-NML, PHAC-86 
NML forwarded their collection of invasive isolates of S. pneumoniae from eight provincial public health 87 
laboratories (Saskatchewan, Manitoba, Ontario, Quebec, Nova Scotia, Prince Edward Island, 88 
Newfoundland and Labrador, and a portion of isolates collected from New Brunswick) to CARA for 89 
antimicrobial susceptibility testing.  For the SAVE study, regional analysis were conducted as Western 90 
(Saskatchewan and Manitoba, n=1352), Central (Ontario and Quebec, n=4107) and Eastern (New 91 
Brunswick, Nova Scotia, Prince Edward Island and Newfoundland and Labrador, n=748). 92 
In total, 6207 invasive isolates of S. pneumoniae collected as part of the SAVE study between 93 
2011 and 2015 were forwarded to the CARA.  Patient gender and age information was available for 5980 94 
(96.3%) and 6072 (97.8%) of the isolates, respectively.  The annual numbers of isolates were: 1379 95 
isolates from 2011, 1285 from 2012, 1138 from 2013, 1210 from 2014, and 1195 from 2015.     96 
Antimicrobial susceptibility testing 97 
Antimicrobial susceptibility testing was performed in the Department of Clinical Microbiology at the 98 
Winnipeg Health Sciences Centre using the standard CLSI broth microdilution method14,15 with custom-99 
designed, in-house prepared, 96-well microtitre panels containing doubling-dilutions of antimicrobial 100 
agents in cation-adjusted Mueller-Hinton broth supplemented to a final concentration of 4% lysed horse 101 
blood.  All isolates were tested against penicillin, ceftriaxone, cefuroxime, clarithromycin, clindamycin, 102 
telithromycin, levofloxacin, moxifloxacin, linezolid, trimethoprim/sulfamethoxazole, doxycycline, 103 
tigecycline, chloramphenicol and vancomycin.  MICs were interpreted as susceptible, intermediate or 104 
resistant using CLSI MIC breakpoints for all antimicrobial agents.15   Multidrug-resistant (MDR) was 105 
defined as resistance to three or more antimicrobial agents selected as antimicrobial class markers 106 
(penicillin, clarithromycin, clindamycin, doxycycline, levofloxacin, trimethoprim/sulfamethoxazole and 107 
chloramphenicol).  In MDR calculations, penicillin resistance was defined using the CLSI breakpoint for 108 
oral penicillin V (MIC, ≥2 mg/L).  Of the 6207 invasive isolates of S. pneumoniae received by CARA for 109 
antimicrobial susceptibility testing, complete susceptibility profiles for all 14 antimicrobial agents were 110 
generated for 6001 isolates; the remaining 206 isolates failed to grow or generated incomplete 111 
susceptibility profiles.  The number of isolates with complete antimicrobial susceptibility testing profiles 112 
per year was 1362 isolates in 2011, 1230 isolates in 2012, 1099 isolates in 2013, 1159 isolates in 2014 113 
and 1151 isolates in 2015. 114 
Serotyping 115 
Serotyping was performed using the Quellung reaction using pool, group, type and factor commercial 116 
antisera (Statens Serum Institute, Copenhagen, Denmark).16  Isolate identity for which a serotype was 117 
not determined by a Quellung reaction was confirmed as S. pneumoniae by rpoB gene sequencing.17  118 
Statistical Analysis 119 
Changes in serotype distribution and multidrug resistance rates between 2011 and 2015 were assessed 120 
for statistically significant differences (P <0.05) using a two-tailed Fisher’s exact test (α=0.05).  The 121 
statistical significance of differences (P <0.05) in the proportion of isolates included in the current 122 
vaccine formulations were assessed using the Chi square test due to the large sample size.   123 
 124 
Results 125 
The annual serotype distribution of invasive isolates of S. pneumoniae collected as part of the SAVE 126 
study in Canada between 2011 and 2015 is presented in Figure 1. The most common serotypes in the 127 
SAVE study overall (n=6207) were 7F (704/11.3%), 19A (599/9.7%), 22F (593/9.6%), 3(491/7.9%), 12F 128 
(291/4.7%), 11A (264/4.3%), 9N (240/3.9%), 8 (239/3.9%), 33F (223/3.6%), and 15A (217/3.5%).  In the 129 
2015 study year (n=1195), the most common serotypes were 22F (101/8.5%), 3 (96/8.0%), 19A 130 
(91/7.6%), 12F (67/5.6%), 33F (65/5.4%), 9N (64/5.4%), 8 (58/4.9%), 7F (49/4.1%), 11A (45/3.8%), 15A 131 
(40/3.3%) and 20 (40/3.3%).   132 
Between 2011 and 2015, statistically significant reductions in the prevalence of serotypes 7F 133 
(P<0.0001), 19A (P<0.0001) and 33A (P<0.0001) were observed.  Statistically significant increases in 134 
serotypes 7C (P=0.034), 8 (P=0.0092), 9N (P=0.0005), 10A (P=0.028), 20 (P<0.0001), 24F (P=0.0008), 29 135 
(P=0.028), 31 (P<0.0001), 33F (P<0.0001), 35B (P=0.021) and 38 (P=0.037) were observed during this 136 
time period.  Notable changes in the rank order of the top ten serotypes were observed during the 137 
study.  Serotype 7F ranked as the most common serotype in 2011 but fell to eighth in 2015 whereas   138 
serotype 19A was only reduced from ranking second to third most common serotype.  Serotypes 22F 139 
and 3 rose in ranking from third and fourth to first and second, respectively.  Serotype 33F ranked as the 140 
ninth most common serotype in 2011 and rose to the fifth position in 2015.  141 
The overall proportion of invasive S. pneumoniae isolates collected in Canada as part of the 142 
SAVE study that were serotypes contained in PCV-7, PCV-10 and PCV-13 are shown in Table 1.     143 
The antimicrobial susceptibility testing results for the ten most common serotypes of invasive S. 144 
pneumoniae in Canada are presented in Table 2.  Reduced susceptibility rates were observed in serotype 145 
19A for penicillin (68.1% based on the IV meningitis breakpoint), ceftriaxone (79.7% based on the IV 146 
meningitis breakpoint), clarithromycin (37.6%), doxycycline (69.3%) and trimethoprim/sulfamethoxazole 147 
(69.6%).  Reduced susceptibility rates were also observed for clarithromycin in serotype 22F isolates 148 
(72.9%) and 12F isolates (37.8%), clarithromycin (73.0%) and trimethoprim/sulfamethoxazole (81.4%) in 149 
serotype 11A isolates, clarithromycin (21.6%) and trimethoprim/sulfamethoxazole (32.0%) in serotype 150 
33F isolates, and penicillin (38.7%), clarithromycin (22.7%) and doxycycline (23.3%) in serotype 15A 151 
isolates.  All isolates were  susceptible to vancomycin.18  Among the top ten serotypes, multidrug 152 
resistance rates greater than five percent were observed for serotypes 15A (57.6%), 19A (26.0%) and 153 
33F (6.3%).  Serotypes that were isolated less frequently in the study but for which multidrug resistance 154 
was observed in more than five percent of isolates included 6B (30%, n=6/20), 9V (22.2%, n=4/18), 14 155 
(21.7%, n=5/23), 15F (100%, n=1/1), 19F (26.8%, n=22/82), 23F (11.1%, n=2/18), 28A (5.9%, n=1/17) and 156 
35A (50%, n=1/2).   157 
Between 2011 and 2015, 372 (6.2%) MDR S. pneumoniae were isolated as part of SAVE.  The 158 
annual rates of multidrug resistance in S. pneumoniae are portrayed in Figure 2.  There was a significant 159 
decrease in multidrug resistance in S. pneumoniae from 8.5% (n=116) in 2011 to 5.6% (n=64) in 2015 160 
(P=0.004) with the lowest proportion seen in 2014 (3.9%, n=45).   161 
MDR S. pneumoniae isolates were identified from all regions of the country with the following 162 
distribution (n / % by region): Western (71 / 5.3%), Central (247 / 6.0%), and Eastern (54 / 7.2%).  Among 163 
the age groups, MDR S. pneumoniae represented 5.3% (12/228) of the isolates from children 0 - <1 years 164 
of age, 11.8% (24/203) of those aged 1 - <2 years, 6.8% (17/251) of those aged 2 - <6 years, 4.5% (9/198) 165 
of those aged 6 - <18 years, 5.4% (67/1233) of adults 18 - < 50 years, 5.1% (83/1627) of those aged 50 - 166 
<65 years, and 6.6% (155/2332) of the elderly ≥ 65 years.  The rate of multidrug resistance was 167 
significantly higher in the 1 - <2 year age category than all other combined age groups (P=0.002).  Similar 168 
numbers of MDR isolates were identified from men and women (MDR n / total n by gender [%]): 169 
185/3213 (5.8%) and 176/2767 (6.4%).   170 
The MDR S. pneumoniae most commonly demonstrated resistance to antimicrobial agents from 171 
three classes (184, 49.5%) , with the most common pattern overall of resistance to clarithromycin, 172 
clindamycin and doxycycline (150, 40.3%) (Supplementary data, Table 1).  Notably, the second most 173 
common pattern was resistance to antimicrobial agents from five classes: clarithromycin, clindamycin, 174 
doxycycline, penicillin and trimethoprim/sulfamethoxazole (110, 29.6%).  Levofloxacin resistance was 175 
only observed in 2% (n=8) of the MDR isolates and only in 2 isolates with an MDR phenotype that 176 
included penicillin.   177 
Multidrug resistance was observed in 32 serotypes of the S. pneumoniae invasive isolates as 178 
shown in Figure 3.  The predominant serotypes among the MDR isolates were 15A (99, 26.6%) and 19A 179 
(155, 41.7%).  The proportion of invasive MDR S. pneumoniae isolates of the SAVE study contained in 180 
PCV-7, PCV-10 and PCV-13 are shown in Table 1.   181 
The demographics of the most common serotypes demonstrating multidrug resistance are 182 
presented in Table 3.  The table includes information on serotypes for which more than 10 MDR isolates 183 
were identified throughout the study, which includes serotypes 3, 6C, 15A, 19A, 19F and 33F.  MDR 184 
serotypes 3, 6C and 33F were only observed in Central Canada.  MDR serotype 3 isolates were only 185 
observed in adults while multidrug resistance was noted in children and adults in the other serotypes.   186 
The most common associations of serotype and specific resistance patterns among the MDR S. 187 
pneumoniae were 19A resistant to clarithromycin, clindamycin, doxycycline, penicillin and 188 
trimethoprim/sulfamethoxazole (n=97) and 15A resistant to clarithromycin, clindamycin and doxycycline 189 
(n=81) (Supplementary data, Table 1).  A single S. pneumoniae resistant to seven antimicrobial agents 190 
was isolated during this study, which was a serotype 23F from a blood culture of a 64 year old female in 191 
2013 from Central Canada. 192 
 193 
Discussion 194 
The ten predominant S. pneumoniae serotypes identified throughout the SAVE study, in order of 195 
frequency of isolation, were 7F, 19A, 22F, 3, 12F, 11A, 9N, 8 and 33F, similar to those reported in the 196 
United Kingdom and the United States.11,19  The serotypes included in the top ten were fairly consistent 197 
throughout the five years of study; however, the ranking order changed somewhat with reductions in 7F 198 
and 19A and increases of serotypes 3, 22F and 33F.  The annual proportion of serotypes 7F and 19A, two 199 
of the serotypes in PCV-13 that were not in PCV-7, decreased significantly during the course of the 200 
study.  Among non-vaccine serotypes, statistically significant reductions in serotype 33A and increases in 201 
serotypes 7C, 8, 9N, 10A, 20, 24F, 29, 31, 33F, 35B and 38 occurred.  Interestingly, the most common 202 
serotypes in IPD cases in Bulgaria, where PCV-10 was used instead of PCV-13, were comparable with 203 
serotypes 3, 19F and 7F predominating.13  The post-PCV-13 reduction in serotypes 7F and 19A and the 204 
increase of serotype 35B observed in this study was also noted very early on in the United States.11   205 
A study on serotype-specific vaccine effectiveness post-licensure of PCV-13 demonstrated 73% 206 
vaccine effectiveness for the serotypes included in PCV-13 that were not previously in PCV-7.20  Of the 207 
PCV-13 specific serotypes, vaccine effectiveness was lowest for serotype 3 (26%) and highest for 208 
serotype 6A (98%) and 7F (91%).20  The effectiveness against serotype 19A was significant at 67% but 209 
notably lower than some of the other serotypes.20  The low vaccine effectiveness for serotype 3 may 210 
explain the ongoing high ranking of this serotype in this study as well as a recent study reported from 211 
the United Kingdom, which noted decreasing trends for all PCV-13 serotypes except serotype 3 following 212 
the routine use of the vaccine.19  A continued predominance of serotype 3 has been reported in a 213 
number of studies around the world.11,13,19  Similarly, the high vaccine effectiveness against serotypes 7F 214 
and 19A may have positively contributed to the significant reductions observed in the proportion of 215 
isolates with serotypes 7F and 19A in the SAVE study.  The small number of serotype 6A isolates 216 
collected during this study may have precluded a notable vaccine effect despite the high effectiveness 217 
reported for PCV-13.   218 
During the most recently analyzed SAVE study year of 2015, only 25.4% of the S. pneumoniae 219 
were serotypes included in PCV-13.  This is a significant reduction from the 54.3% reported for invasive 220 
S. pneumoniae isolates as part of a pre-PCV-13 surveillance study performed by CARA between 2007 and 221 
2009.21  The high proportion of non-vaccine serotypes causing IPD after only a few years of PCV-13 use is 222 
similar to the epidemiology observed following the implementation of PCV-7.   223 
Among the most common serotypes of invasive S. pneumoniae isolated in this study, high rates 224 
of antimicrobial resistance were most notable for serotypes 15A and 19A.  An increase in the rates of 225 
penicillin and erythromycin non-susceptibility in serotypes 15A and 19A was observed in the United 226 
States following the introduction of PCV-7.5  In France, decreased susceptibility to penicillin and 227 
erythromycin resistance post-PCV-13 implementation was frequently observed in serotypes 15A, 24F 228 
and 35B but not in 12F.12  The decreased penicillin susceptibility reported for serotype 15A isolates in 229 
France is consistent with our study in which serotype 15A had the lowest penicillin susceptibility rate 230 
(38.7% with the IV meningitis breakpoint) of all the serotypes analyzed.  Clarithromycin resistance was 231 
very commonly observed in our Canadian study with high rates reported for serotypes 11A, 12F, 22F and 232 
33F.  In addition to penicillin and clarithromycin resistance, serotype 15A isolates were frequently 233 
resistant to doxycycline and serotype 19A isolates demonstrated high levels of resistance to doxycycline 234 
and trimethoprim/sulfamethoxazole.  In France, tetracycline resistance was common in serotypes 12F, 235 
15A and 24F isolates while resistance to trimethoprim/sulfamethoxazole was most frequently observed 236 
with serotype 24F.12  In contrast, the 12F isolates in our study were generally susceptible to doxycycline.   237 
Despite the consistent reports of some serotype-specific susceptibility patterns, such as the high 238 
levels of penicillin non-susceptibility in serotype 15A, a number of differences in serotype-specific 239 
susceptibility patterns have been observed in various regions of the world.   Differences in antimicrobial 240 
prescribing practices between countries are likely one of many contributing factors to these 241 
observations.12  A significant association between high rates of outpatient antibiotic prescribing and an 242 
increased proportion of IPD caused by non-susceptible S. pneumoniae was documented in the United 243 
States.22   Another recent study conducted in the United States demonstrated that regional variability in 244 
the rates of penicillin resistance in non-PCV-13 serotypes was influenced by multiple factors including 245 
the geographic heterogeneity in serotype distribution and the serotype-specific differences in rates of 246 
penicillin resistance.23     247 
Subsequent to the introduction of PCV-13 in Canada, rates of multidrug resistance in S. 248 
pneumoniae decreased significantly from 8.5% in 2011 to 5.6% in 2015 (P=0.004).  Similar rates of 249 
multidrug resistance were reported in the United Kingdom with 6.2% of invasive isolates tested between 250 
2005 and 2014 demonstrating resistance to penicillin, erythromycin and tetracycline.19  In that study, 251 
multidrug resistance in invasive isolates was most commonly observed, with rates greater than 5%, in 252 
serotypes 6B, 15A, 19A and 19F.19   These observations are consistent with those in our study where a 253 
large proportion of the commonly isolated serotypes 15A, 19A and 33F and the infrequently isolated 6B, 254 
9V, 14, 15F, 19F, 23F, 28A and 35A demonstrated a MDR phenotype.  MDR serotypes circulating in 255 
Bulgaria post-PCV-10 were similar and included 6A, 6C, 15A, 19A, 19F and 23A.13  The similarity of the 256 
predominant MDR serotypes is notable despite the selective pressure of a different vaccine.  The overall 257 
decrease in multidrug resistance noted in our study was likely driven by the decrease in the proportion 258 
of circulating strains that were 19A, which was a predominant serotype and is frequently MDR.  This 259 
conclusion is consistent with other large scale studies evaluating antimicrobial resistance in S. 260 
pneumoniae subsequent to PCV-13.12 261 
Between 2011 and 2015, only 56.7% of the MDR S. pneumoniae evaluated in this study were 262 
PCV-13 serotypes.  Although this proportion is lower than that reported in our pre-PCV-13 study where 263 
88% of MDR isolates were PCV-13 serotypes21, it remained consistent throughout the SAVE study.   264 
MDR S. pneumoniae were isolated from all regions of Canada included in the SAVE study with 265 
slightly higher rates observed in the Eastern region.  MDR isolates were also collected from patients of 266 
all ages; however, the rate of multidrug resistance was significantly higher for children 1 to <2 years of 267 
age than in all other age groups (P=0.002).  Children under the age of 2 are frequently prescribed 268 
antimicrobials for the treatment of common infections, such as otitis media,24  which may provide the  269 
selective pressure contributing to the high rates of multidrug resistance observed within this age group.     270 
 Among the MDR isolates, the most common resistance pattern observed was resistance to 271 
clarithromycin, clindamycin and doxycycline.  This specific phenotype represented 40.3% of the MDR 272 
isolates and was a component of the phenotype of 86.6% of the MDR isolates in this study.  The 273 
frequent association of resistance between clarithromycin and clindamycin reflects the prevalence of 274 
the erm(B) resistance determinant in the S. pneumoniae in this study.25  Janoir et al. reported that the 275 
predominant MDR phenotype post-PCV-13 in France was resistance to penicillin, erythromycin and 276 
tetracycline.12  Although that unique phenotype was rare in our study, representing less than 1% of the 277 
isolates, MDR phenotypes that included resistance to penicillin, clarithromycin and doxycycline were 278 
observed in 41% of the isolates.  Importantly, levofloxacin, which is one of the recommended 279 
antimicrobial agents for the treatment of penicillin-resistant isolates, was only observed in 2% of the 280 
MDR isolates and very rarely in association with penicillin resistance. 281 
The most significant limitations of this study are the lack of participation of all provinces in 282 
Canada and that it does not represent incidence data.  Accordingly, we can only demonstrate changes in 283 
the proportion of serotypes causing IPD from the eight Canadian provinces.   The lack of isolates from 284 
British Columbia and Alberta results in an underrepresentation of Western region isolates and may skew 285 
the regional analysis.  Additionally, the specific antimicrobial agents tested were not universally 286 
consistent with the comparator studies.  Antimicrobial susceptibility results and the MDR comparisons 287 
were made using agents representing an antimicrobial class.  For example, many of the comparator 288 
studies reported erythromycin and tetracycline results instead of the clarithromycin and doxycycline 289 
reported in the SAVE study. 290 
A significantly greater proportion of the invasive S. pneumoniae isolated as part of the SAVE 291 
study overall, as well as the subset of isolates that were MDR, were serotypes included in PCV-13 292 
compared to the other currently available vaccines (P<0.0001).  However, only 25.4% of S. pneumoniae 293 
overall and 56.3% of the MDR isolates were PCV-13 serotypes in the 2015 SAVE study collection.  These 294 
epidemiological shifts are critical to monitor in order to provide optimal empiric therapy and guide 295 
future vaccine development.  The SAVE study has highlighted a number of critical serotypes to monitor 296 
including serotype 33F, which is increasing in frequency, is included in the top ten most common 297 
serotypes and demonstrates multidrug resistance in more than 5% of isolates.  Other notable serotypes 298 
are 24F, of which more than 5% of isolates are MDR and is increasing in frequency, as well as serotypes 299 
15A and 19A that continue to predominate in both frequency of isolation and rates of multidrug 300 
resistance.  301 
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Table 1. The annual proportion of invasive S. pneumoniae isolates with serotypes contained in the 396 
pneumococcal conjugate vaccines, SAVE 2011-2015. 397 
Phenotype Vaccine Study 
Total (% 
[n]) 
Year (% [n]) 
2011 vs 
2015 (P) 2011 2012 2013 2014 2015 
All isolates PCV7 4.7 (291) 5.6 (77) 4.9 (63) 4.6 (52) 3.6 (44) 4.6 (55) 0.3 
 
PCV10 
16.6 
(1029) 
26.7 
(368) 
20.6 
(265) 
14.9 
(170) 9.7 (117) 9.1 (109) <0.0001 
 
PCV13 
34.9 
(2164) 
48.0 
(662) 
39.6 
(509) 
33.7 
(383) 
25.4 
(307) 
25.4 
(303) <0.0001 
MDR PCV7 10.8 (40) 6.9 (8) 9.6 (8) 12.5 (8) 17.8 (8) 12.5 (8) 0.3 
 PCV10 11.6 (43) 8.6 (10) 10.8 (9) 12.5 (8) 17.8 (8) 12.5 (8) 0.4 
 PCV13 56.7 (211) 54.3 (63) 54.2 (45) 65.6 (42) 55.6 (25) 56.3 (36) 0.9 
Table 2.  Antimicrobial susceptibility testing results for the ten most common serotypes of invasive S. pneumoniae, SAVE 2011-2015. 398 
Serotype 
(na) 
% Susceptible/MIC90 (mg/L) 
%MDRb 
Penicillin 
(IV, 
meningitis) 
Penicillin (IV, 
nonmeningitis) 
Ceftriaxone 
(meningitis) 
Ceftriaxone 
(nonmeningitis) 
Clarithromycin Levofloxacin SXTc Doxycycline 
7F (694) 99.3/≤0.03 100/≤0.03 99.9/≤0.12 100/≤0.12 97.3/≤0.03 99.7/1 99.6/0.5 96.5/≤0.25 0.4 
19A (596) 68.1/4 86.1/4 79.7/1 94.1/1 37.6/>32 99.7/1 69.6/8 69.3/4 26.0 
22F (591) 99.5/≤0.03 99.8/≤0.03 99.8/≤0.12 99.8/≤0.12 72.9/2 98.8/1 99.0/0.25 99.0/≤0.25 0.8 
3 (457) 99.8/≤0.03 100/≤0.03 100/≤0.12 100/≤0.12 96.1/≤0.03 100/1 98.9/≤0.12 89.3/1 2.6 
12F (291) 99.7/≤0.03 100/≤0.03 100/≤0.12 100/≤0.12 37.8/4 100/1 98.3/0.5 97.3/≤0.25 1.4 
11A (263) 98.5/≤0.03 100/≤0.03 99.2/≤0.12 100/≤0.12 73.0/2 99.6/1 81.4/8 98.5/≤0.25 0.8 
9N (240) 98.3/≤0.03 100/≤0.03 99.6/≤0.12 100/≤0.12 91.7/0.25 100/1 96.7/0.5 97.9/≤0.25 0.4 
8 (238) 98.7/≤0.03 100/≤0.03 99.6/≤0.12 100/≤0.12 99.2/≤0.03 100/1 98.7/0.25 95.4/≤0.25 0.4 
33F (222) 99.5/≤0.03 100/≤0.03 100/≤0.12 100/≤0.12 21.6/16 100/1 32.0/2 84.7/0.5 6.3 
15A (172) 38.7/1 100/1 94.8/0.5 100/0.5 22.7/>32 100/1 91.9/0.5 23.3/16 57.6 
an of each serotype for which complete suscpetibility data was available, bMDR, multidrug reistance; cSXT, trimethoprim/sulfamethoxazole399 
Table 3. Demographics of the common (n>10) multidrug resistant invasive S. pneumoniae isolates by 400 
serotype, SAVE 2011 – 2015. 401 
Serotype (n) 
Canadian 
Region 
Age Group (years) 
0-<1 1-<2 2-<6 6-<18 18-<50 50-<65 ≥65 
3 (12) Western 
      
  
  Central 
    
2 3 7 
  Eastern               
6C (11) Western 
      
  
  Central 
  
1 
 
1 4 4 
  Eastern             1 
15A (99) Western 1 1 
  
5 1 3 
  Central 2 4 2 
 
8 18 46 
  Eastern           2 6 
19A (155)* Western 4 4 1 2 18 8 9 
  Central 2 6 7 5 12 13 28 
  Eastern   2 3   6 9 11 
19F (22) Western 1 
    
4   
  Central 
  
1 
 
1 
 
9 
  Eastern   1       3 2 
33F (14) Western 
      
  
  Central 1 3 2 
 
1 4 3 
  Eastern               
*The age was unknown for 5 MDR isolates of 19A 402 
Figure 1.  Annual serotype distribution of invasive S. pneumoniae isolates (n≥20) collected in the SAVE study, 2011 – 2015.  403 
 404 
Serotypes for which less than 20 isolates were collected between 2011 and 2015 include: 23F (n=18), 1 (n=17), 5 (n=17), 28A (n=17), 13 (n=11), 405 
37 (n=10), 24B (n=8), 11B (n=7), 6D (n=5), 9L (n=3), 10F (n=3), 24 (n=3), 27 (n=3), 25A (n=2), 35A (n=2), 22A (n=2), and 1 isolate each of serotypes 406 
7A, 7B, 9A, 10B, 12A, 15F, 18A, 35C, 42 and 45. 407 
Figure 2.  Annual rates of multidrug resistance in invasive S. pneumoniae isolates collected in the SAVE 
study, 2011 – 2015. 
 
Figure 3.  Serotype distribution of multidrug resistance in invasive S. pneumoniae isolates collected in 
the SAVE study, 2011 – 2015 (n=372). 
 
